多发性骨髓瘤非编码RNA的研究进展

doi:10.3969/j.issn.1673-8640.2018.03.017

摘要/Abstract

摘要：

非编码RNA（ncRNA）是一类很少或不能合成蛋白质的RNA,包括微小RNA（miRNA）和长链非编码RNA（lncRNA）等RNA。miRNA分子是短的非编码RNA,在实体肿瘤和造血系统恶性肿瘤中有异常表达,在基因表达的转录后调节中起重要的作用。lncRNA在哺乳动物包括人类中,已被证明在癌组织中异常表达并参与致癌或肿瘤抑制的过程。文章就ncRNA在多发性骨髓瘤（MM）中的生物学功能和作为潜在作用靶点的治疗价值作一综述。

关键词: 非编码RNA, 多发性骨髓瘤, 病理学, 生物学标志物, 治疗

Abstract:

Non-coding RNA （ncRNA）is a class of RNA with a few or no capacity of protein synthesis. It includes microRNA （miRNA）and long non-coding RNA （lncRNA）. MiRNA is the shortest ncRNA expressed aberrantly in solid and hematopoietic malignancies,where it plays a pivotal function as post-transcriptional regulators of gene expression. LncRNA has been shown to be expressed aberrantly in cancer tissue and to be involved in oncogenic or tumor suppressive process in mammalian and human. This review mainly describes the biological function and potential therapeutic role of ncRNA as drug or target.

Key words: Non-coding RNA, Multiple myeloma, Pathology, Biomarker, Therapy

中图分类号:

R446.1

纪伟, 吴洪坤, 周琳. 多发性骨髓瘤非编码RNA的研究进展[J]. 检验医学, 2018, 33(3): 264-268.

JI Wei, WU Hongkun, ZHOU Lin. Research progress of non-coding RNA in multiple myeloma[J]. Laboratory Medicine, 2018, 33(3): 264-268.

参考文献 35

1	BIANCHI G, ANDERSON K C. Understanding biology to tackle the disease: multiple myeloma from bench to bedside, and back[J]. CA Cancer J Clin, 2014,64(6): 422-444.
2	ALLART-VORELLI P, PORRO B, BAGUET F, et al. Haematological cancer and quality of life: a systematic literature review[J]. Blood Cancer J, 2015,5: e305.
3	MITSIADES C S, MITSIADES N, MUNSHI N C, et al. Focus on multiple myeloma[J]. Cancer Cell, 2004,6(5): 439-444.
4	KUMAR S K, RAJKUMAR S V, DISPENZIERI A, et al. Improved survival in multiple myeloma and the impact of novel therapies[J]. Blood, 2008,111(5): 2516-2520.
5	BERTONE P, STOLC V, ROYCE T E, et al. Global identification of human transcribed sequences with genome tiling arrays[J]. Science, 2004,306(5705): 2242-2246.
6	International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome[J]. Nature, 2004,431(7011): 931-945.
7	AMBROS V. The functions of animal microRNAs[J]. Nature, 2004, 431(7006): 350-355.
8	YU Z, TOZEREN A, PESTELL R G. Function of miRNAs in tumor cell proliferation[J]. Springer Netherlands, 2013,431(7006): 13-27.
9	MERCER T R, DINGER M E, MATTICK J S. Long non-coding RNAs: insights into functions[J]. Nat Rev Genet, 2009,10(3): 155-159.
10	PONTING C P, OLIVER P L, REIK W. Evolution and functions of long noncoding RNAs[J]. Cell, 2009,136(4): 629-641.
11	KORNIENKO A E, GUENZL P M, BARLOW D P, et al. Gene regulation by the act of long non-coding RNA transcription[J]. BMC Biol, 2013,11: 59.
12	FATICA A, BOZZONI L. Long non-coding RNAs: new players in cell differentiation and development[J]. Nat Rev Genet, 2014,15(1): 7-21.
13	WANG X, LI C, WANG Y, et al. Myeloma cell adhesion to bone marrow stromal cells confers drug resistance by microRNA-21 up-regulation[J]. Leuk Lymphoma, 2011,52(10): 1991-1998.
14	ROCCARO A M, SACCO A, THOMPSON B, et al. MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma[J]. Blood, 2009,113(26): 6669-6680.
15	SAITO Y, LIANG G, EGGER G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells[J]. Cancer Cell, 2006,9(6): 435-443.
16	BANDRES E, AGIRRE X, BITARTE N, et al. Epigenetic regulation of microRNA expression in colorectal cancer[J]. Int J Cancer, 2009,125(11): 2737-2743.
17	BALLABIO E, MITCHELL T, VAN KESTER M S, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential[J]. Blood, 2010,116(7): 1105-1113.
18	WONG K Y, LIANG R, SO C C, et al. Epigenetic silencing of MIR203 in multiple myeloma[J]. Br J Haematol, 2011,154(5): 569-578.
19	ZHANG W, WANG Y E, ZHANG Y, et al. Global epigenetic regulation of microRNAs in multiple myeloma[J]. PLoS One, 2014,9(10): e110973.
20	MIN D J, EZPONDA T, KIM M K, et al. MMSET stimulates myeloma cell growth through microRNA-mediated modulation of c-MYC[J]. Leukemia, 2013,27(3): 686-694.
21	HAO M, ZHANG L, AN G, et al. Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells[J]. J Hematol Oncol, 2011,4:37.
22	ROCCARO A M, SACCO A, MAISO P, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression[J]. J Clin Invest, 2013,123(4): 1542-1555.
23	RONCHETTI D, AGNELLI L, TAIANA E, et al. Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma[J]. Oncotarget, 2016,7(12): 14814-14830.
24	SUN C Y, SHE X M, QIN Y, et al. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF[J]. Carcinogenesis, 2013,34(2): 426-435.
25	PICHIORRI F, SUH S S, LADETTO M, et al. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis[J]. Proc Natl Acad Sci U S A, 2008,105(35): 12885-12890.
26	JONES C I, ZABOLOTSKAYA M V, KING A J, et al. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma[J]. Br J Cancer, 2012,107(12): 1987-1996.
27	KUBICZKOVA L,KRYUKOV F,SLABY O,et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance[J]. Haematologica, 2014,99(3): 511-518.
28	ZHUANG W, GE X, YANG S, et al. Upregulation of lncRNA MEG3 promotes osteogenic differentiation of mesenchymal stem cells from multiple myeloma patients by targeting BMP4 transcription[J]. Stem Cells, 2014,33(6):1985-1997.
29	CHO S F, CHANG Y C, CHANG C S, et al. MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression[J]. BMC Cancer, 2014,14: 809.
30	ZHOU M, ZHAO H, WANG Z, et al. Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma[J]. J Exp Clin Cancer Res, 2015,34: 102.
31	AMODIO N, DI MARTINO M T, FORESTA U, et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1[J]. Cell Death Dis, 2012,3: e436.
32	LÖFFLER D, BROCKE-HEIDRICH K, PFEIFER G, et al. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer[J]. Blood, 2007,110(4): 1330-1333.
33	LEONE E, MORELLI E, DI MARTINO M T, et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth[J]. Clin Cancer Res, 2013,19(8): 2096-2106.
34	PICHIORRI F, SUH S S, ROCCI A, et al. Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development[J]. Cancer Cell, 2010,18(4): 367-381.
35	ROCCARO A M, SACCO A, MAISO P, et al. BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression[J]. J Clin Invest, 2013,123(4): 1542-1555.

[1]	赵沱, 白鹏飞, 孙婧, 程涛. 血清lncRNA NEAT1在急性心肌梗死患者中的表达及其临床意义[J]. 检验医学, 2023, 38(9): 897-900.
[2]	王腾飞, 陈珊, 安和兵, 周蕾. 急性白血病患者外周血lncRNA CRNDE、miR-384表达及其临床意义[J]. 检验医学, 2023, 38(7): 686-691.
[3]	乌有弘, 宋云霄, 朱勇, 葛雯, 卞晓波, 袁文华, 赵智赟. 血脂水平在冠心病患者冠状动脉狭窄评估和治疗中的价值[J]. 检验医学, 2023, 38(6): 584-589.
[4]	张敏, 王彬宇, 迟伟群, 刘禹. 外泌体非编码RNA作为疾病诊断生物标志物的研究进展[J]. 检验医学, 2023, 38(6): 594-598.
[5]	高锋. 新型肿瘤标志物的临床应用——前景与挑战[J]. 检验医学, 2023, 38(4): 303-306.
[6]	陈哲, 张灵, 刘洁, 王霞, 张斌, 高炳华. 血清miR-326与治疗相关性血液系统恶性肿瘤患者化疗敏感性和预后的关系[J]. 检验医学, 2023, 38(3): 251-256.
[7]	周福荣, 李龑杼, 刘勇敢. lncRNA SNP在结直肠癌易感性预测和预后评估中的应用[J]. 检验医学, 2023, 38(12): 1206-1210.
[8]	畅慧君, 张敏, 张其相. 血清Hcy水平与接受静脉溶栓治疗急性脑梗死患者短期预后的相关性[J]. 检验医学, 2023, 38(11): 1057-1061.
[9]	高建朝, 王思思, 张志生, 张京力, 李晓霞, 马科, 冯志林, 周海丰, 王展海. miR-206、miR-125、miR-21在乳腺癌新辅助化疗疗效和预后评估中的价值[J]. 检验医学, 2023, 38(11): 1062-1068.
[10]	邢宝宝, 曹银芳. sd-LDL-C/LDL-C比值对AMI患者介入治疗后支架内再狭窄的预测价值[J]. 检验医学, 2023, 38(10): 941-945.
[11]	刘伟, 郭战萍, 郝迎军, 宋媛媛. 胶质硅法和鞣花酸法APTT检测临床应用效果比较[J]. 检验医学, 2023, 38(10): 983-986.
[12]	郭霜, 刘红莉, 李娅. EB病毒相关胃癌迁移、侵袭相关miRNA和lncRNA研究进展[J]. 检验医学, 2023, 38(10): 987-996.
[13]	王瑞娟, 李超, 段丽娟, 尚淼, 杨如玉. lncRNA RBM5-AS1在急性髓系白血病中的表达及其临床意义[J]. 检验医学, 2023, 38(1): 39-45.
[14]	王粟, 丁立, 姜文容, 缪应新, 张艳梅, 赵虎. 高毒力肺炎克雷伯菌耐药性和治疗策略研究进展[J]. 检验医学, 2023, 38(1): 81-86.
[15]	汪雨卿, 张越, 徐稳, 崔中奇. 铁死亡相关lncRNA结肠癌预后风险模型的构建及临床应用[J]. 检验医学, 2022, 37(8): 720-728.